Theranexus partners with Synerlab for a breakthrough in the treatment of Niemann-Pick C

Theranexus and Synerlab Group have announced a partnership for the production of Mig-OS, a drinkable formulation of miglustat, for children with Niemann-Pick disease type C. This project, based on a patented and approved technology, marks a major step forward in treating this rare neurodevelopmental disease. The European market launch is planned for 2026, following registration with the EMA.

Synerlab will ensure industrial manufacturing according to European standards. This partnership underlines the commitment of both companies to meet critical medical needs. With a market estimate of over €200 million, it also represents a significant commercial opportunity for Theranexus.